Haemodynamic effects of the flavonoid quercetin in rats revisited

Misha F. Vrolijk1,2 | Helma van Essen1 | Antoon Oppenhuizen1,3 | Aalt Bast1,2 | Ben J. Janssen1

1Department of Pharmacology & Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
2Faculty of Science and Engineering, Maastricht University Campus Venlo, Venlo, The Netherlands
3Office for Risk Assessment and Research (BuRO), Netherlands Food and Consumer Product Safety Authority (NVWA), Utrecht, The Netherlands

Correspondence
Dr Ben J. Janssen, Department of Pharmacology & Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, PO Box 616, Maastricht 6200 MD, The Netherlands.
Email: b.janssen@maastrichtuniversity.nl

Funding information
Netherlands Food and Consumer Product Safety Authority, Grant/Award Number: V/090143/1

Background and Purpose: The flavonoid quercetin increased the in vitro potency of the α1-antagonist tamsulosin to reduce phenylephrine-dependent arterial contractions by 10-fold. To examine if this supplement–drug interaction luxates hypotensive and orthostatic events in vivo, several set of studies were conducted in spontaneously hypertensive (SHR) and normotensive (Wistar Kyoto [WKY]) rats.

Experimental Approach: First, in rats pretreated with quercetin or its vehicle, responses to phenylephrine and tamsulosin were examined. Second, tamsulosin-induced changes in renal, mesenteric, hindquarter and carotid conductance were compared in quercetin- and vehicle-treated rats instrumented with Doppler flow probes. Animals were also placed on a tilt table to record regional haemodynamic changes to orthostatic challenges. Third, adult SHR were instrumented with telemeters to measure 24-hr patterns of BP. Recordings were made before and during a 5-week oral treatment of quercetin. Finally, pre-hypertensive SHR were treated with quercetin from 4 to 8 weeks of age and arterial pressure was measured at 8 and 12 weeks.

Key Results: Pretreatment with quercetin did not influence the responses to phenylephrine and tamsulosin, in neither WKY nor SHR. While tamsulosin treatment and tilting lowered BP and increased conductance in all vascular beds, effect size was not influenced by pretreatment with quercetin. Prolonged treatment with quercetin, in either prehypertensive SHR or adult SHR with established hypertension did not lower BP.

Conclusions and Implications: Cumulatively, these data demonstrate that quercetin does not amplify haemodynamic effects of tamsulosin or tilting in vivo in rats and has no effect on BP development in SHR.

Abbreviations: HR, heart rate; MAP, mean arterial pressure; SHR, spontaneously hypertensive rats; WKY, Wistar Kyoto.
**1 | INTRODUCTION**

Epidemiological studies have revealed inverse associations between the intake of dietary flavonoids and mortality from cardiovascular diseases (Geleijnse, Launer, Van der Kuip, Hofman, & Wittman, 2002; Hertog, Feskens, Hollman, Katan, & Kromhout, 1993; Knekt, Jarvinen, Reunanen, & Maatela, 1996; McCullough et al., 2012; Mink et al., 2007; Yochum, Kushi, Meyer, & Folsom, 1999). **Quercetin** is the most abundant flavonoid in fruits and vegetables and is the best studied flavonoid. Prominent effects attributed to quercetin include antioxidant, anti-inflammatory, anti-allergic, anti-carcinogenic and antihypertensive, as well as anti-atherogenic activities (Boots, Drent, de Boer, Bast, & Haenen, 2011; Kleemann et al., 2011; Patel et al., 2018). Quercetin is therefore regarded to have potentially beneficial health effects and is widely available as a food supplement (Boots, Haenen, & Bast, 2008).

Duarte et al. (2001) reported that oral intake of quercetin (10 mg·kg$^{-1}$) lowers arterial BP in spontaneously hypertensive rats (SHR). The same treatment regimen also attenuated $\upgamma$-NAME-induced hypertension in rats (Perez-Vizcaino et al., 2002). Studies on isolated vessels isolated from these rat models suggested that the vasodilator effect was inversely proportional to vessel size and occurred especially in the mesenteric vascular bed (Perez-Vizcaino et al., 2002). While other studies have explored the antihypertensive effects of quercetin further, controversy exists about the potential mechanisms involved, as well the magnitude of the effect and the potential clinical relevance (Carlstrom et al., 2007; Larson, Symons, & Jallil, 2012; Monteiro, Franca-Silva, Alves, Porpino, & Braga, 2012; Sanchez et al., 2006). This is possibly due to publication bias (Serban et al., 2016), since negative studies on quercetin have been rarely published. Recently, we discovered that in isolated mesenteric arteries, quercetin increased the potency of tamsulosin to inhibit phenylephrine-induced contractions by a factor $\geq 10$ (Vrolijk et al., 2015). Tamsulosin is prescribed to male patients to facilitate urination by blocking $\alpha_1$-adrenoceptors in the prostate and neck of the bladder. Blockade of vascular $\alpha_1$-adrenoceptors has been associated with the occurrence of orthostatic (postural) hypotensive (Akiyama, Hora, Yamagishi, & Kitazawa, 2002; Noble et al., 1997). The present study was designed to explore if the supplement–drug interaction between quercetin and tamsulosin would also occur in vivo in rats. To investigate the possible haemodynamic mechanisms involved, four series of experiments were performed assessing acute as well as chronic effects of oral and intravenously administered quercetin in both SHR and Wistar Kyoto (WKY) rats.

**2 | METHODS**

**2.1 | Animals, ethical statement and husbandry**

All animal procedures were carried out with the approval of the Animal Ethics Committee of the Maastricht University and are in accordance with the editorial guidelines on experimental design and analysis in pharmacology (Curtis et al., 2018). The experimental studies were conducted in accordance to those published in the European Directive 2010/63/EU or earlier versions. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the editorial on reporting animal studies (McGrath & Lilley, 2015). Group sizes were a priori determined using mandatory power calculations based on the outcome of comparable previous studies.

Series of experiments were performed in inbred hypertensive SHR/NCrl and normotensive WKY rats/NCrl. These rat models have been used extensively to examine the antihypertensive potency of agents in vivo (Doris, 2017). All rats were delivered by a commercial breeder (Charles River, Germany). Unless specified otherwise, animals were housed in groups in standard cages, in a temperature-controlled (22 ± 2°C) room, with lights on from 07:00 a.m. to 07:00 p.m. and had free access to food and water throughout. Various experimental interventions required single housing of the animals. Details are outlined in the various studies below.

**2.2 | Experimental procedures and surgery**

**2.2.1 | Study 1: Does quercetin amplify the $\alpha_1$-adrenoceptor blocking properties of tamsulosin in vivo?**

Since SHR are considered to have elevated sympathetic tone and are more sensitive to effects of $\alpha$-antagonists, the first series of studies were conducted in SHR as well as WKY rats. Studies were done in eight SHR/NCrl (4 females + 4 males) and eight WKY rats/NCrl (4 females + 4 males). The male and female rats were housed in the same room but not in the same cage. The menstrual cycle was not determined in the females. All rats received pre-operatively buprenorphine (0.01 mg·kg$^{-1}$, s.c.). Rats were placed in a box and anaesthesia was induced by inhalation of isoflurane (4%). Anaesthesia...
was maintained by inhalation of isoflurane (1.5–2.5%) through a nose cone. A catheter was inserted into the lower abdominal aorta via the femoral artery. A second line was inserted into the femoral vein. Both catheters were tunnelled subcutaneously to the neck of the rats, filled with heparinized saline (5 IU·ml⁻¹) and closed with a metal plug. After regaining consciousness, analgesia was maintained by subcutaneous injection of carprofen (5 mg·kg⁻¹). This injection was repeated 24 hr later. Rats were now housed individually and allowed to recover from surgery for 72 hr. The instrumented rats were subjected to the following two experimental protocols.

**Protocol 1A**

Four SHR/NCrI (2 females + 2 males) and four WKY rats/NCrI (2 females + 2 males) were dosed twice with quercetin by administering the agent (5 mg·kg⁻¹, i.v., max. 300 μl) once immediately after placement of the catheters and once 48 hr after surgery. The dose was based on studies that were conducted before and the route of administration was chosen to overcome the low oral bioavailability of quercetin making sure that the system was loaded with the supplement (Duarte et al., 2001; Jalili et al., 2006; Li et al., 2009; Perez-Vizzaino et al., 2002; Sanchez et al., 2006). Control rats were injected with vehicle solution (cyclodextrin 15% w/v in saline). Twenty-four hours after the second loading dose, rats were placed in a small cage containing some of the bedding of the original home cage to limit stress reactions. The arterial and venous lines were extended to record arterial BP and to allow injections of drug solutions. Haemodynamics were allowed to stabilize for at least 1 hr before the actual recordings started. First, baseline BP was recorded for 30 min. Then, BP changes to four incremental dosages of phenylephrine (0.1, 0.3, 1.0 and 3.0 μg·kg⁻¹, i.v.) were determined. The volume that was maximally injected intravenously was 250 μl (50 μl of the phenylephrine solution followed by 200 μl of saline to flush the line). The four injections were given in a 15-min interval period. Next, quercetin or its vehicle was administered intravenously, in the same dose and volume as before, after which the baseline BP was recorded for 15 min and the phenylephrine challenges were repeated. Then, tamsulosin (3 μg·kg⁻¹, i.v., max. 300 μl) was administered and phenylephrine challenges were repeated at 10, 40 and 120 min after the tamsulosin injection. After completion of this experiment, catheters were flushed with heparinized saline and rats were allowed to rest in their home cage for at least additional 48 hr.

**Protocol 1B**

Two days later, the same rats were connected to the measuring equipment as described in protocol 1A. After stabilization of haemodynamics, baseline BP was recorded for 30 min. Then, quercetin (5 mg·kg⁻¹, i.v.) or the vehicle solution was administered again and BP was recorded for another 15 min. Thereafter, BP changes were obtained in response to cumulatively increasing intravenous dosages of tamsulosin (0.3, 1.0, 3.0, 10, 30 and 100 μg·kg⁻¹) given at 10- to 12-min intervals. Injection volumes never exceeded 200 μl. At the end of the experiment the rats received a terminal dose of anaesthetic (i.v.: pentobarbital 200 mg·kg⁻¹).

### 2.2.2 Study 2: Regional vascular effects of quercetin in the absence and presence of tamsulosin

As it was reported that quercetin preferentially dilated in rat mesenteric arteries (Perez-Vizzaino et al., 2002), this study was designed to explore which vascular beds were targeted by the food additive and if the interaction with tamsulosin would unmask effects of quercetin in other vascular beds in adult male and female WKY rats (RRID: RGDr61103).

All rats were pretreated with 0.01 mg·kg⁻¹ of buprenorphine subcutaneously and anaesthesia was induced and maintained as described in protocol 1A. When pedal withdrawal reflexes were absent, a ventral midline abdominal incision was made, intestines were retracted and target vessels were isolated by blunt dissection. Miniature pulsed Doppler flow probes were fixed around the left renal artery, the superior mesenteric artery, the distal abdominal aorta and the left common carotid artery to measure renal, mesenteric, hind-quarter and carotid blood flow, respectively, as described previously (Janssen, van Essen, Struyker Boudier, & Smits, 1989). The wires of the probes were exteriorized and the peritoneal cavity was closed with sutures to limit hypothermia and fluid loss. Catheters were inserted in the femoral artery and vein to facilitate the recording of arterial pressure and injections of agents, respectively. Next, while maintaining the isoflurane anaesthesia, rats were secured on a tilt table. Wires and catheters were connected and body temperature was kept at 37°C via a servo-controlled system with the sensor probe placed in the rectum of the rat. The pressure sensor was placed at the level of the heart of the animal. The current set-up has been drawn in Figure S2. In this way, haemodynamic responses were recorded during orthostatic challenges (45° head-up) of 2-min duration. The potential of such a tilt protocol has been published before by Akiyama, Hora, Yamagishi, and Kitazawa(2002) who compared orthostatic responses with various α-adenoreceptor antagonists in rats.

The following protocol was carried out: - Baseline haemodynamics were recorded for 15 min. Then the rats received either (5 mg·kg⁻¹, i.v.) quercetin (n = 13, mean body weight ± SD, 263 ± 57 g) or its vehicle cyclodextrin (n = 10, 259 ± 55 g). Recordings were made for another 10 min. Then, tamsulosin (3.0 μg·kg⁻¹, i.v.) was given and recordings were continued for additional 30 min. The preparation was subjected to orthostatic challenges before and after injection of the quercetin/vehicle solution and at 3, 10, 20 and 30 min after tamsulosin was applied. At the end of the study, the preparation was terminated by an intravenous injection of pentobarbital (200 mg·kg⁻¹).

### 2.2.3 Study 3: BP effects of oral administration of quercetin in SHR equipped with telemetric devices

Twelve male adult SHR (age 14–16 weeks, 280–320 g) were instrumented with implants (PA-C40, Data Sciences International, St. Paul, MN, USA) to record arterial BP by telemetry. Anaesthesia was induced by isoflurane and perioperative analgesia was maintained.
with buprenorphine. The catheter was inserted in the abdominal aorta with its tip just below the renal arteries and the probe was placed in the peritoneal cavity as sutured the ventral abdominal muscle wall. The abdomen and skin were closed in layers with resorbable sutures. The animals were allowed to recover from surgery for 10–14 days. Animals were single housed now because the telemetric devices do not allow acquisition of multiple signals from one cage.

The following protocol was conducted: Baseline BP, heart rate (HR) and locomotor activity were measured during three full 24-hr cycles every week for a period of 6 weeks. The first week of this period (week 0) served as the baseline period. Next, from weeks 1 to 5, one group of SHR (n = 6, body weight 305 ± 23 g) received standard food to which quercetin was added. By measuring food consumption, the approximate daily oral intake of quercetin was estimated to be about 10 mg kg⁻¹. The SHR control group (n = 6, 294 ± 15 g) received the standard food only.

### 2.2.4 Study 4: Effects of transient treatment on BP and renal haemodynamics in pre-hypertensive SHR

Four-week-old male SHR/NCrl (n = 12) were treated with quercetin (1 g kg⁻¹) mixed through the standard food from weeks 4 to 8 of age. Control SHR (n = 12) received normal food. At the age of 8 weeks, BP was measured in conscious conditions by the same method as described in study 1. After these measurements, under isoflurane anaesthesia, renal blood flow was directly measured with a flow probe (Transonic Systems Inc., VB series 0.5 mm, Ithaca, NY, USA). Rats were killed by exsanguination and organs were harvested for later analysis. The same procedures were repeated in a subgroup of SHR (n = 6) that was retained until 12 weeks of age after the transient challenge with quercetin. Data were compared with those obtained in historic non-treated controls (Heijnen, Van Essen, Schalkwijk, Janssen, & Struijker-Boudier, 2014). Blood plasma samples were frozen and prepared for the later analysis of quercetin levels with the aid of a 6550 iFunnel Q-TOF LC/MS (Agilent Technologies) similarly as described by Yang et al. (2016).

### 2.3 Data and statistical analysis

In Studies 1, 2 and 4, arterial BP was measured via fluid filled catheters that were coupled to a pressure transducer. Signals were digitally sampled (at >1 kHz) and processed by software (IDEEQ) developed by Maastricht Instruments BV (Maastricht University, The Netherlands) to extract mean arterial pressure (MAP) and HR on a beat-to-beat basis. In study 2, wires from the flow probes were connected to a Doppler flow meter (Crystal Biotech, Holliston, MA, USA) and processed by the same IDEEQ system in a comparable way.

In the protocols of study 1, baseline variables were obtained by averaging MAP and HR over at least 30-min periods. Peak responses to phenylephrine were calculated as well as average 5-min values of MAP and HR before any new injection was given. Peak responses of MAP following the incremental phenylephrine injections were averaged to acquire a cumulative index for the sensitivity to phenylephrine in each condition.

In study 2, baseline values of MAP, HR and regional blood flows were determined when the preparation had stabilized. Responses to drug injections were measured as mean values averaged over 5–10 min after injection. Responses to the 2-min orthostatic tilt challenge were examined at 5, 10, 15, 30, 60, and 120 s after the stimulus. Regional conductance was derived by dividing the flow values by the pressure values.

In the telemetry study (#3), signal samples of 10-s duration were taken every 5 min for three consecutive 24-hr periods every week, including arbitrary units for locomotor activity. MAP and HR were derived from the waveform signal using the Dataquest ART System (Data Science, Inc.). Values of MAP, HR and locomotor activity were averaged over 1-hr periods. The 24-hr cycle was constructed by averaging the hourly over the three consecutive days.

In study 4, baseline parameters were obtained by averaging MAP and HR over at least 30-min periods. Baseline values were obtained over a 15-min period when the animal was under anaesthesia and the renal flow probe was in place.

In studies 1 and 2, a two-way ANOVA was applied to examine the potential effects of treatment (quercetin vs. vehicle) and strain (WKY rats vs. SHR) on the haemodynamic parameters collected. In study 3, a two-way ANOVA was applied to delineate the effect of treatment (quercetin vs. control) and time (week 0 vs. week 5). The post hoc tests were conducted only if F in ANOVA achieved P < .05 and there was no significant variance inhomogeneity.

In Study 4, between-group differences (quercetin vs. control) were only compared at one time point and unpaired Student's t-tests were applied. Sample sizes subjected to statistical analysis included at least 6 animals per group (n = 6), where n = number of independent values.

All statistical analyses were performed with GraphPad Prism 5.02 (GraphPad Prism, RRID:SCR_002798; GraphPad Software Inc., La Jolla, CA, USA). The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology.

### 2.3.1 Drugs

Quercetin, phenylephrine, tamsulosin, and cyclodextrin were purchased from Sigma-Aldrich. The specific use of these drugs is specified in detail in each protocol above. Buprenorphine hydrochloride (Buprecare) and isoflurane (IsoFlo) were obtained from AST Farma, Oudewater, The Netherlands. Carprofen (Norocarp) was obtained from Norbrook Laboratories, Newry, UK.

### 2.4 Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARmacology (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019).
# RESULTS

## 3.1 Study 1: Does quercetin amplify the α1-adrenoceptor antagonist action of tamsulosin in vivo?

### 3.1.1 Baseline characteristics

Body weight, baseline BP and HR were comparable in vehicle- and quercetin-pretreated SHR and WKY rats during the days that rats were subjected to the haemodynamic measurements in protocols 1A and 1B. As expected, BP was higher in SHR than in WKY rats. These data can be found in Figure S1.

**Protocol 1A**

Injections of phenylephrine induced a dose-dependent increase in BP in all rats (Figure 1a). The magnitude of the pressor responses to phenylephrine was not different in vehicle- or quercetin-pretreated animals. Intravenous administration of tamsulosin (3 μg·kg⁻¹) attenuated the BP increments evoked by phenylephrine and resulted in a significant rightward shift of the pressor response curves. The extent of this rightward shift was not different between vehicle- and quercetin-pretreated animals. As shown in Figure 1b,c, in WKY rats as well as SHR, cumulative phenylephrine-induced pressor effects were time-dependently inhibited by tamsulosin with the effect of tamsulosin wearing off at 40 min after injection. The duration of the blockade by tamsulosin was not different between vehicle- and quercetin-pretreated rats.

**Protocol 1B**

The combined effect of a single dose of quercetin and cumulative doses of tamsulosin on haemodynamics

In vehicle-pretreated unanaesthetized rats, dose–response curves of tamsulosin (0.3–100 μg·kg⁻¹) mildly reduced BP in WKY rats (maximal effect −10 mmHg, Figure 2a), whereas potent reductions were observed in unanaesthetized SHR (maximal effect −40 mmHg, Figure 2b). HR increased dose dependently following tamsulosin injections in both SHR and WKY rats (Figure 2c,d). The magnitude of these changes in HR was not different for vehicle- or quercetin-pretreated rats.

## 3.2 Study 2: Regional vascular effects of quercetin in the absence and presence of tamsulosin

Vehicle or quercetin injections did not alter BP, HR or regional (carotid, hindquarter, mesenteric and renal) conductance in anaesthetized WKY rats (Figure 3). Injection of tamsulosin (3 μg·kg⁻¹) reduced BP by about 50% and increased regional conductance maximally by 300% in the various vascular beds (Figures 3 and S3). HR remained stable during the interventions. The haemodynamic changes evoked by tamsulosin were nearly back to baseline within 30 min after injection. The duration of the regional vascular effects induced by tamsulosin were not different between vehicle- or quercetin-treated rats. At regular intervals in this protocol, rats were subjected to a 2-min orthostatic challenge. The orthostatic effects on BP and mesenteric conductance are summarized in Figure 4. As shown in this figure, tilting by 45° caused a rapid 10% decrease in
FIGURE 2  Comparison of the cumulative tamsulosin-induced depressor responses as recorded in conscious normotensive Wistar Kyoto rats (WKY, \( n = 8 \)) and spontaneously hypertensive rats (SHR, \( n = 8 \)) in vehicle- and quercetin-treated animals. (a, b) The changes in mean arterial pressure (MAP) in both strains. (c, d) The associated changes in heart rate (HR). While absolute depressor responses to tamsulosin were significantly greater in SHR than in WKY, blood pressure responses to \( \alpha \)-adrenoceptor blockade were not very different between vehicle- and quercetin-treated rats.

FIGURE 3  Comparison of the regional haemodynamic changes (mean arterial pressure (MAP; Figure 3a) and heart rate (HR; Figure 3b)) induced by acute intravenous injection of quercetin (\( n = 8 \)) or its vehicle solution (\( n = 8 \)) as recorded in isoflurane anaesthetized Wistar Kyoto rats instrumented with Doppler flow probes to record simultaneously blood velocity changes as observed in the four indicated vascular beds (carotid conductance (Figure 3c), hindquarter conductance (Figure 3d), mesenteric conductance (Figure 3e) and renal conductance (Figure 3f)). Data on tamsulosin-induced haemodynamic changes were taken at 3, 10, 20 and 30 min after injection of the \( \alpha_1 \)-antagonist. Compared with vehicle treatment, quercetin treatment did not amplify tamsulosin-induced changes in any of the vascular beds. Absolute baseline values (±SD) of MAP and HR under anaesthesia were not significantly different, being 70 ± 11 mmHg and 311 ± 34 bpm in the vehicle-treated (\( n = 13 \)) and 78 ± 11 mmHg and 325 ± 28 bpm in the quercetin-treated (\( n = 10 \)) rats, respectively.
BP, which was associated with a 10% rise in mesenteric conductance. The magnitude of the effect was constant at all time points in the protocol and there was no difference between quercetin- and vehicle-treated rats.

3.3 | Study 3: BP effects of oral administration of quercetin in SHR equipped with telemetric devices

Figure 5 compares the 24-hr patterns of BP, HR and locomotor activity in the two groups of SHR designated to receive normal food (control) or quercetin for 5 weeks at 10 mg kg$^{-1}$ day$^{-1}$. While a considerable variation can be observed in all variables within 24-hr, none of these data were different between the two treatment groups at this time point (week 0). The oral intake of quercetin did not alter these 24-hr patterns. In both groups, comparable age-related increments in BP and reductions in HR were observed.

3.4 | Study 4: Effects of transient treatment on BP and renal haemodynamics in pre-hypertensive SHR

The 4-week supplementation of quercetin to the food of young SHR (4 weeks of age) resulted in a significant growth retardation. As shown in Table 1, at 8 weeks of age, food and water intake was significantly lower when SHR were placed on the food enriched with quercetin. This was associated with significant reductions (about 5–10%) in body weight, organ weight and tibia length. Arterial BP measured in unanaesthetized conditions was lower in quercetin-supplemented SHR (134 ± 11 mmHg) compared with controls (145 ± 9 mmHg). Renal vascular resistance as determined by direct flow measurements under anaesthesia was not different between groups. When SHR were allowed to eat normal food again for an additional period of 4 weeks, many of the differences that were observed at 8 weeks were normalized except for tibia length and lung weight. Notably, arterial pressures were very comparable at 12 weeks of age (controls: 130 ± 9 mmHg) compared with controls (135 ± 10 mmHg).
The present study revisited the in vivo haemodynamic effects of quercetin in rats. Remarkably, all of the measurements indicated that quercetin does not lower arterial BP in vivo, either after acute intravenous administration or after chronic oral feeding. Moreover, quercetin did not affect the haemodynamics of anaesthetized rats that were exposed to an orthostatic challenge. Hence, the study failed to translate the recent in vitro observation showing an interaction between quercetin and tamsulosin to the in vivo situation (Vrolijk et al., 2015).

Reports on the BP-lowering action of quercetin in humans are not univocal. In the most recent systematic review and meta-analysis, a small (−3 mmHg) effect was found (Serban et al., 2016). Significant BP reductions occurred only when doses of quercetin exceeded 500 mg day−1. For doses <500 mg day−1, the size of the effect was no different from placebo. In most experimental animal studies, modest BP reductions by quercetin have been reported (Duarte et al., 2001; Jalili et al., 2006). Only in one rat study, quercetin failed to lower BP (Carlstrom et al., 2007). To our knowledge, other negative studies have not been published. Mechanisms and the magnitude and relevance of the antihypertensive effects of quercetin remain unclear. In rat studies, dosing of quercetin is usually well controlled and above 5 mg kg−1 day−1. Therefore, differences in BP-lowering efficacy of quercetin have not been attributed to the dose of the nutraceutical but rather to other factors such as (a) the age of the rats, (b) the type of model and severity of hypertension, (c) the particular form of quercetin administered and (d) the route of delivery of the agent (Carlstrom et al., 2007). The present study combines data from four sub-studies on the haemodynamic effects of quercetin. The whole data set embraces many aspects of the four factors mentioned above and includes acute and chronic effects of quercetin, being orally and intravenously administered, in unaesthetized and anaesthetized conditions and in pre-hypertensive and normotensive rats.

**4 | DISCUSSION**

The present study revisited the in vivo haemodynamic effects of quercetin in rats. Remarkably, all of the measurements indicated that plasma quercetin levels that were reached after 4 weeks of treatment in young SHR were 7.89 ± 1.91 ng ml−1 (n = 8), while in control rats (n = 7) no quercetin could be detected. It should be noted that these values represent quercetin levels that were present about 5–10 hr after the last ability of the rats to eat. With an approximate plasma half-life of quercetin of 0.8 hr in rats, estimated plasma levels were probably at least a factor $2^3 = 32$ higher (about 256 ng ml−1, corresponding to 0.8 μmol L−1).

**FIGURE 5** Comparison of telemetry-based 24-hr patterns of mean arterial pressure (MAP; Figure 5a) and heart rate (HR; Figure 5b) and locomotor activity (Figure 5c) in adult spontaneously hypertensive rats as recorded over 3 days at the age of 16–17 weeks (defined as week 0) and 5 weeks later (defined as week 5) after chronic oral feeding of quercetin (10 mg kg−1, n = 6) or normal food (n = 6). In both treatment arms, MAP rose significantly with ageing of the spontaneously hypertensive rats and HR fell. These age-related changes in haemodynamics were not different between animals on control food and those on quercetin.

**4.1.1. Study 1: Does quercetin amplify the α1-adrenoceptor antagonist properties of tamsulosin in vivo?**

Acute intravenous administration of quercetin did not modify α1-receptor-mediated changes in haemodynamics evoked by phenylephrine in conscious SHR and WKY rats. This indicates that quercetin has no interference with vascular α1-receptors in vivo. The food additive did also not augment tamsulosin-mediated reductions in arterial BP. While the tamsulosin-induced fall in BP was larger in SHR than in WKY rats, the presence of quercetin did not reduce BP any further, excluding a pharmacodynamic interaction. Since quercetin did not modify the duration of the BP-lowering effect in either, a kinetic interaction between tamsulosin and quercetin is unlikely. It has been suggested that quercetin might modify the baroreflex-mediated changes in HR (Monteiro et al., 2012). However, the present data do not support this suggestion since the HR increments that occurred in response to the tamsulosin-induced fall in arterial pressure were not different between quercetin- and vehicle-treated rats. The magnitude of the haemodynamic responses to quercetin and tamsulosin was also compared between male and female rats. Sex differences were not detected in either protocols (data not shown). Thus, while quercetin
increased the potency of tamsulosin in mesenteric arteries in vitro (Vrolijk et al., 2015), such an effect could not be reproduced in vivo.

4.1.2. Study 2: Regional vascular effects of quercetin in the absence and presence of tamsulosin

Although quercetin did not amplify tamsulosin-induced systemic reductions in arterial BP, this finding does not exclude that quercetin might modify regional vascular responses to the \(\alpha_1\)-antagonist in a differential way. To examine this possibility, regional vascular responses to tamsulosin were compared in the presence and absence of quercetin. Attention was paid particularly to responses that occurred in the mesenteric vascular bed, because it was the arteries of this organ that the in vitro interaction between tamsulosin and quercetin was originally observed (Vrolijk et al., 2015). The data showed that injection of tamsulosin in anaesthetized WKY rats reduced BP rapidly (within 3 min) by more than 40 mmHg and that this was caused by an increase in vascular conductance (dilation) in all four of the vascular beds being monitored. The duration of these increases were found to be unchanged quercetin treatment. These observations also exclude a regional vascular preference for the observed in vitro interaction between the drug and the food additive. To investigate if quercetin could augment tamsulosin-related orthostatic haemodynamic responses, rats were challenged to a 45° head-up tilt. While this was associated with a 5- to 10-mmHg decreases in arterial BP and increases in mesenteric conductance, the magnitude of the responses to tilting was not different between vehicle- and quercetin-treated rats. These combined present observations in rats do not support the hypothesis that quercetin may aggravate orthostatic challenges by tamsulosin in patients. It has been proposed that tamsulosin has already a low tendency to cause orthostasis in humans because of its specific binding properties to the plasma protein alpha-1-glycoprotein (Noble et al., 1997). Because quercetin binds predominantly to plasma albumin (Diniz et al., 2008) and not alpha-1-glycoprotein, such a kinetic interaction is also not likely. Alternatively, it is possible that in vivo flow-mediated endothelial factors may have overruled the ex vivo interaction between tamsulosin and quercetin. Using in vivo imaging techniques, it was found that 7-mono-O-(\(\beta\)-hydroxyethyl)-rutoside, a semi-synthetic derivative of quercetin, was present inside

| Parameters | Treatment | Quercetin | Control | Quercetin | Control |
|------------|-----------|-----------|---------|-----------|---------|
| Age        | 8 weeks   | 8 weeks   | 12 weeks| 12 weeks  |
| Observations | N = 15   | N = 12    | N = 8   | N = 6     |
| Body weight (g) | 167 ± 18 | 156 ± 11* | 258 ± 21| 239 ± 10  |
| Metabolic parameters | | | |
| Urine (ml per 24 hr) | 7.4 ± 2.1 | 6.2 ± 1.7 | 11.0 ± 1.8 | 10.3 ± 4.4 |
| Food intake (g per 24 hr) | 19.7 ± 2.9 | 15.9 ± 2.4* | 23.2 ± 2.1 | 21.8 ± 3.3 |
| Water intake (ml per 24 hr) | 27.0 ± 4.0 | 21.9 ± 2.6* | 31.3 ± 4.7 | 30.0 ± 5.7 |
| Organ weight | | | |
| Heart (g) | 0.65 ± 0.05 | 0.62 ± 0.04 | 1.00 ± 0.08 | 0.94 ± 0.03 |
| Kidney, left (g) | 0.66 ± 0.07 | 0.61 ± 0.04* | 0.89 ± 0.06 | 0.83 ± 0.05 |
| Kidney, right (g) | 0.67 ± 0.07 | 0.62 ± 0.03* | 0.90 ± 0.06 | 0.84 ± 0.04 |
| Lungs (g) | 0.83 ± 0.08 | 0.80 ± 0.05 | 1.10 ± 0.11 | 0.97 ± 0.05* |
| Tibia length (cm) | 3.24 ± 0.08 | 3.17 ± 0.06* | 3.71 ± 0.07 | 3.59 ± 0.03* |
| Cardiovascular variables (unanæsthetized) | | | |
| MAP (mmHg) | 145 ± 11 | 134 ± 9* | 179 ± 8 | 180 ± 8 |
| HR (bpm) | 412 ± 41 | 396 ± 18 | 382 ± 26 | 393 ± 26 |
| RBF measurement (anaesthesia) | | | |
| MAP (mmHg) | 93 ± 17 | 88 ± 17 | 116 ± 40 | 112 ± 16 |
| RBF (ml·min\(^{-1}\)·per 100 g KW) | 3.39 ± 1.01 | 3.64 ± 0.94 | 3.41 ± 1.05 | 3.21 ± 0.66 |
| Conductance (units) | 0.04 ± 0.01 | 0.04 ± 0.01 | 0.03 ± 0.02 | 0.03 ± 0.01 |

Note. In a subgroup of spontaneously hypertensive rats, after the 4-week treatment period, quercetin was withdrawn and replaced by normal food. At the age of 12 weeks, the same measurements were performed.

Abbreviations: HR, heart rate; KW, kidney weight; MAP, mean arterial pressure; RBF, renal blood flow.

*Compared with control, 8 weeks, \(P < .05\).

†Compared with control, 12 weeks, \(P < .05\).

‡Compared with control, 12 weeks, \(P < .01\).
the endothelial cells of intact arteries (Lemmens et al., 2014). The significance of this observation needs further exploration.

4.1.3. Study 3: BP effects of oral administration of quercetin in SHR equipped with telemetric devices

Significant antihypertensive properties for quercetin have been mainly reported in rat studies in which BP was measured indirectly by tail cuff plethysmography. This procedure has the limitation in that the animals need to be warmed and restrained and provides systolic pressure readings over a few cardiac cycles that are not stress free (Kurtz et al., 2005). Typically, in such studies in SHR, systolic pressures >220 mmHg were noted and quercetin-induced reductions in systolic pressures were in the order of 5–20%. In contrast, in telemetry studies, rats are housed in their home cage and data are collected over a full 24-hr period under stress-free conditions. Using the latter approach, 24-hr BP profiles were compared in adult SHR before and after a 5-week treatment with quercetin. In both the control- and quercetin-treated rats, BP rose by about 15 mmHg between weeks 16 and 22 of age. At no point in time over this measurement period, a BP-lowering effect of quercetin was observed. Because 24-hr profiles of HR and locomotor activity were also very comparable, the data suggest that quercetin treatment did also not influence behavioural activity of the rats. To our knowledge, this is the first telemetric study that reports the absence of BP-lowering action of quercetin.

4.1.4. Study 4: Effects of transient treatment on BP and renal haemodynamics in prehypertensive SHR

While the addition of 0.1% quercetin through the regular rat chow led to biologically effective plasma concentrations of quercetin (Boots et al., 2011), the treatment regimen was associated with significant reductions in food and water intake in young pre-hypertensive SHR. Probably, the young rats disliked the taste of the quercetin aglycone as significant growth retardation occurred. Hence, the lower arterial BP that was found after 4 weeks of ingesting quercetin should not be attributed to a direct effect of the food additive but should rather be interpreted as being a consequence of the retarded general development of the SHR, thereby delaying the progression of high BP in this strain. This explanation is supported by the observation that when normal food was allowed for an additional period of 4 weeks, catch-up growth occurred and BP rose to levels as observed in untreated SHR. In pre-hypertensive SHR, the renal vascular bed is among one of the vascular beds that exhibit reduced vascular conductance over a wide vasomotor range (Evenwel, Kasbergen, & Struyker-Boudier, 1983; Kett, Bergstrom, Alcorn, Bertram, & Anderson, 2001). For this reason, renal vascular conductance was compared by direct blood flow measurements in SHR receiving quercetin enriched or control food. Renal vascular resistance was not different between these treatments. Heijnen et al. (2014) and Baumann et al. (2007) showed that pre-hypertensive treatment with an angiotensin receptor antagonist in the same developmental period in SHR induces a long-term antihypertensive effect. In the current study, no such effects were found for quercetin. Potentially, quercetin-related effects are more evident in conditions of high renin-angiotensin-aldosterone system activity, such as in rats in which the abdominal aorta was clipped suprarenally (Jalili et al., 2006).

Overall, after extensively investigation of the effects of quercetin on the haemodynamics of rats, our results show that quercetin administration does not affect haemodynamics in both SHR and WKY rats. The literature suggests that the mode of administration may be important in determining the protective effects of quercetin (Carlstrom et al., 2007) and that beneficial effects may be mediated by metabolites produced by gut microbiota (Santangelo, Silvestrini, & Mancuso, 2019). The present study was not designed to examine such potential explanations. We administered the most common form of quercetin in doses that would be present in the human diet or when taken as food supplement.

In summary, different modes of delivery of quercetin, different exposure times, different ages of the rats and different approaches were used to study haemodynamic effects of quercetin in the present study. Not only is the interaction between quercetin and tamsulosin investigated in vivo for the first time, but also telemetry and the tilt table were used for the first time to study haemodynamic effects of quercetin in rats. We have shown that the in vitro discovered interaction between quercetin and tamsulosin could not be validated in vivo.

ACKNOWLEDGEMENTS
Part of the study was supported by Grant V/090143/1 donated by the Netherlands Food and Consumer Product Safety Authority. We thank Dr C. Korstanje for his critical review of the manuscript.

AUTHOR CONTRIBUTIONS
M.F.V., A.B., and B.J.J. conceived and designed the studies. H.v.E. and B.J.J. conducted the experiments. M.F.V., H.v.E., and B.J.J. performed the data analysis. M.F.V., A.O., A.B., and B.J.J. interpreted the data. M.F.V. and B.J.J. wrote the original draft. H.v.E., A.O., and A.B. reviewed and revised the manuscript for publication.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR
This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BJR guidelines for Design & Analysis and Animal Experimentation and as recommended by funding agencies, publishers, and other organizations engaged with supporting research.

REFERENCES
Akiyama, K., Hora, M., Yamagishi, R., & Kitazawa, M. (2002). Effects of KMD-3213, a uroselective α1A-adrenoceptor antagonist, on the
VROLIJK ET AL.

A. Diniz, A., Escuder-Gilabert, L., Lopes, N. P., Villanueva-Camanas, R. M., Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H.,… Carlstrom, J., Symons, J. D., Wu, T. C., Bruno, R. S., Litwin, S. E., & Jalili, T. (2017). Genetics of hypertension: An assessment of progress. British Journal of Pharmacology, 174(Suppl 1), S21–S141.

M. Janssen, B. J., van Essen, H., Struyker Boudier, H. A., & Smits, J. F. (1989). Hertog, M. G., Feskens, E. J., Hollman, P. C., Katan, M. B., & Kromhout, D. (1993). Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet, 342, 1007–1011.

Jallit, T., Carlstrom, J., Kim, S., Freeman, D., Jin, H., Wu, T. C.,… Symons, J. D. (2006). Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. Journal of Cardiovascular Pharmacology, 47, 531–541.

Janssen, B. J., van Essen, H., Struyker Boudier, H. A., & Smits, J. F. (1989). Hemodynamic effects of activation of renal and mesenteric sensory nerves in rats. The American Journal of Physiology, 257, R29–R36.

Kett, M. M., Bergstrom, G., Alcorn, D., Bertram, J. F., & Anderson, W. P. (2001). Renal vascular resistance properties and glomerular protection in early established SHR hypertension. Journal of Hypertension, 19, 1505–1512.

Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. British Journal of Pharmacology, 160, 1577–1579.

Kleemann, R., Verschuren, L., Morrison, M., Zadaela, S., van Erk, M. J., Wielinga, P. Y., & Kostraa, T. (2011). Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis, 218, 44–52.

Knekt, P., Jarvinen, R., Reunanen, A., & Maatela, J. (1996). Flavonoid intake and coronary mortality in Finland: A cohort study. BMJ, 312, 478–481.

Kurtz, T. W., Griffin, K. A., Bidani, A. K., Davison, R. L., Hall, J. E., & Sub-committee of P. et al. (2005). Recommendations for blood pressure measurement in humans and experimental animals: Part 2: Blood pressure measurement in experimental animals: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, e22–e33.

Larson, A. J., Symons, J. D., & Jallit, T. (2012). Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy and mechanisms. Advances in Nutrition, 3, 39–46.

Lemmens, K. J., van de Wier, B., Vaes, N., Ghosh, M., van Zandvoort, M. A., van der Vijgh, W. J.,… Haen, G. R. (2014). The flavonoid 7-mono-(p-hydroxyethyl)-rutoside is able to protect endothelial cells by a direct antioxidant effect. Toxicology in Vivo, 28, 538–543.

Li, H., Zhao, X., Ma, Y., Zhai, G., Li, L., & Lou, H. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release, 133, 238–244.

McCullough, M. L., Peterson, J. J., Patel, R., Jacques, P. F., Shah, R., & Dwyer, J. T. (2012). Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. The American Journal of Clinical Nutrition, 95, 454–464.

McGrath, J. C., & Lilley, E. (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. British Journal of Pharmacology, 172(13), 3189–3193. https://doi.org/10.1111/bph.12955

Mink, P. J., Scharford, C. G., Barraj, L. M., Harnack, L., Hong, C. P., Nettleton, J. A., & Jacobs, D. R. Jr. (2007). Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. The American Journal of Clinical Nutrition, 85, 895–909.

Monteiro, M. M., Frana-Silva, M. S., Alves, N. F., Porpori, S. K., & Braga, V. A. (2012). Quercetin improves baroreflex sensitivity in spontaneously hypertensive rats. Molecules, 17, 12977–13008.

Noble, A. J., Chess-Williams, R., Coulwood, C., Furukawa, K., Uchiyima, T., Korstanje, C., & Chapple, C. R. (1997). The effects of tamsulosin, a high affinity antagonist at functional α1A- and α1D-adrenoceptor subtypes. British Journal of Pharmacology, 120, 231–238.

Patel, R. V., Mistry, B. M., Shinde, S. K., Syed, R., Singh, V., & Shin, H. S. (2018). Therapeutic potential of quercetin as a cardiovascular agent. European Journal of Medicinal Chemistry, 155, 889–904.

Perez-Vizcaino, F., Ibarra, M., Cogolludo, A. L., Duarte, J., Zaragoza-Arnaez, F., Moreno, L.,… Tamargo, J. (2002). Endothelin-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. The Journal of Pharmacology and Experimental Therapeutics, 302, 62–72.

Sanchez, M., Galisteo, M., Vera, R., Villar, I. C., Zarzuella, A., Tamargo, J.,… Duarte, J. (2006). Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. Journal of Hypertension, 24, 75–84.
Santangelo, R., Silvestrini, A., & Mancuso, C. (2019). Ginsenosides, catechins, quercetin and gut microbiota: Current evidence of challenging interactions. *Food and Chemical Toxicology, 123*, 42–49.

Serban, M. C., Sahebkar, A., Zanchetti, A., Mikhailidis, D. P., Howard, G., Antal, D., ... Lip, G. Y. (2016). Effects of quercetin on blood pressure: A systematic review and meta-analysis of randomized controlled trials. *Journal of the American Heart Association, 5*(7); 15, e002713. https://doi.org/10.1161/JAHA.115.002713

Vrolijk, M. F., Haenen, G. R., Opperhuizen, A., Jansen, E. H., Schiffers, P. M., & Bast, A. (2015). The supplement–drug interaction of quercetin with tamsulosin on vasorelaxation. *European Journal of Pharmacology, 746*, 132–137.

Yang, L. L., Xiao, N., Li, X. W., Fan, Y., Alolga, R. N., Sun, X. Y., ... Qi, L. W. (2016). Pharmacokinetic comparison between quercetin and quercetin 3-O-β-glucuronide in rats by UHPLC-MS/MS. *Scientific Reports, 6*, 1-9, 35460. https://doi.org/10.1038/srep35460

Yochum, L., Kushi, L. H., Meyer, K., & Folsom, A. R. (1999). Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. *American Journal of Epidemiology, 149*, 943–949.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Vrolijk MF, van Essen H, Opperhuizen A, Bast A, Janssen BJ. Haemodynamic effects of the flavonoid quercetin in rats revisited. *Br J Pharmacol.* 2020; 177:1841–1852. [https://doi.org/10.1111/bph.14955](https://doi.org/10.1111/bph.14955)